ADMA Biologics (ADMA) director exercises options and gifts 60,000 shares

Rhea-AI Filing Summary

ADMA Biologics director Lawrence P. Guiheen reported a mix of option exercises and charitable estate planning transactions. On March 13, 2026, he exercised stock options to acquire 30,000 shares of common stock at $3.66 per share, increasing his direct equity stake. On March 17, 2026, he made bona fide gifts totaling 60,000 shares of common stock, including 30,000 shares transferred directly and 30,000 shares gifted to the 2019 Guiheen Irrevocable Trust, over which he retains control but disclaims beneficial ownership except for any pecuniary interest. After these transactions, he holds 105,520 shares directly, with additional shares held indirectly through irrevocable trusts as described in the footnotes.

Insights

Insider trading and governance analyst

Routine option exercise paired with non-market gifts, net effect neutral.

The reporting person exercised stock options to acquire 30,000 shares of ADMA Biologics common stock at an exercise price of $3.66. No same-day sales are reported, so this looks like an exercise-and-hold pattern that increases direct ownership.

He also made bona fide gifts totaling 60,000 shares, with 30,000 shares transferred to the 2019 Guiheen Irrevocable Trust and 30,000 shares given directly, both coded as gifts (G). Gifts are non-market transfers with no sale proceeds and usually carry limited signaling value about the insider’s view of the stock.

Following these moves, he reports 105,520 shares held directly and additional indirect holdings through irrevocable trusts as described in the footnotes. The filing shows no open‑market buying or selling, and the transactionSummary indicates neutral net buy/sell shares, suggesting this is largely routine compensation and estate planning activity rather than a major change in stance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guiheen Lawrence P.

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

465 STATE ROUTE 17

(Street)

RAMSEY NJ 07446

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		M		30,000	A	$3.66	135,520(1)	D
Common Stock	03/17/2026		G(2)		30,000	D	$0	105,520(1)	D
Common Stock	03/17/2026		G(2)		30,000	A	$0	30,000	I	See footnote(3)
Common Stock								50,990	I	See footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.66	03/13/2026		M			30,000(5)	(6)	06/06/2027	Common Stock	30,000	$0	23,837	D

Explanation of Responses:

1. Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 94,830 shares of common stock owned by the Reporting Person.

2. This transaction involved the Reporting Person's gift of 30,000 shares of Issuer common stock to the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE (the "2019 Guiheen Irrevocable Trust"), over which Mr. Guiheen retains control. The Reporting Person disclaims beneficial ownership of the securities held by the 2019 Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

3. Includes 30,000 shares of common stock held in the 2019 Guiheen Irrevocable Trust.

4. Includes 50,990 shares of common stock held in the Lawrence P Guiheen Irrevocable Trust 1.

5. The Reporting Person is exercising this option due, in part, to its near-term expiration date.

6. These options vested in twenty-four equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

	/s/ Lawrence P. Guiheen, by Michael A. Goldstein as Attorney-in-fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ADMA director Lawrence P. Guiheen report on this Form 4 for ADMA?

Lawrence P. Guiheen reported an option exercise and two gifts. He exercised stock options for 30,000 ADMA common shares at $3.66, then made bona fide gifts totaling 60,000 shares, including transfers to an irrevocable trust associated with his family.

Did Lawrence P. Guiheen buy or sell ADMA common stock on the open market in this filing?

No open-market buys or sells were reported. The filing shows an option exercise coded M, which converts options into shares, and two G-coded bona fide gifts. There are no P or S codes, so no reported open-market purchases or sales of ADMA shares.

How many ADMA shares does Lawrence P. Guiheen hold directly after these transactions?

He holds 105,520 ADMA common shares directly after the transactions. This figure comes from the March 17, 2026 gift entry, which reports total direct shares following the disposition, and excludes additional indirect holdings through irrevocable trusts noted in the footnotes.

What stock option activity did Lawrence P. Guiheen report for ADMA Biologics?

He exercised stock options for 30,000 ADMA shares at $3.66 each. The derivative transaction, coded M, converted a Stock Option (Right to Buy) into common stock and was undertaken in part due to the option’s near-term expiration, according to a footnote.

How are the gifted ADMA shares held after Lawrence P. Guiheen’s transfers?

Some gifted ADMA shares are now held in family trusts. Footnotes explain that 30,000 shares are held in the 2019 Guiheen Irrevocable Trust and 50,990 shares in the Lawrence P. Guiheen Irrevocable Trust 1, reflecting indirect holdings associated with the reporting person.